Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Auspex

Pharma deals during October 2012

As pharma companies ramp up their activity after the summer, this month's dealmakers included Pfizer, AstraZeneca, Merck & Co and Bayer

- PMLiVE

Bayer makes $1.2bn bid for Schiff Nutrition, reports Q3

Boosts consumer health division as group sales climb 11.5 per cent

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Pharma deals during September 2012

In this regular review of deals we focus on transactions announced during September 2012

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

Teva pulls generic version of antidepressant Wellbutrin XL in US

FDA says copy is not equivalent to branded drug

- PMLiVE

Sanofi acquires Colombian pharma manufacturing firm Genfar

Expands its Latin American generics portfolio

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

- PMLiVE

Bayer buys Teva animal health unit

Deal valued at $145m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links